Trust Investment Advisors Buys New Stake in Globus Medical, Inc. $GMED

Trust Investment Advisors purchased a new position in shares of Globus Medical, Inc. (NYSE:GMED) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 11,928 shares of the medical device company’s stock, valued at approximately $1,028,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Invesco Ltd. boosted its stake in Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after acquiring an additional 3,595,339 shares in the last quarter. Bank of Montreal Can increased its position in shares of Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after purchasing an additional 3,351,380 shares in the last quarter. Sculptor Capital LP increased its position in shares of Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock worth $162,936,000 after purchasing an additional 667,850 shares in the last quarter. Madison Avenue Partners LP lifted its holdings in shares of Globus Medical by 3.0% in the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock valued at $229,167,000 after purchasing an additional 76,588 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after purchasing an additional 1,908,795 shares during the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Price Performance

Shares of NYSE GMED opened at $75.99 on Thursday. The stock has a fifty day moving average price of $82.66 and a 200 day moving average price of $87.22. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The company has a market cap of $10.32 billion, a PE ratio of 17.67, a P/E/G ratio of 1.63 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 27.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on GMED. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Royal Bank Of Canada boosted their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Piper Sandler decreased their price objective on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Monday, June 15th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Wells Fargo & Company cut their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 18.38% of the stock is currently owned by insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.